{
    "nctId": "NCT04179318",
    "briefTitle": "the New Geneswell BCT in Vitro Diagnosis of Breast Cancer Prognosis",
    "officialTitle": "A Retrospective, International Multicenter, Single Arm Clinical Trial of the New Geneswell BCT in Vitro Diagnosis of Breast Cancer Prognosis",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "Comparative assessment between risk groups",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* The patients were diagnosed with invasive breast cancer with positive hormone receptor (including positive estrogen receptor or progesterone receptor) and negative human epidermal growth factor receptor 2 (HER2)\n* Axillary lymph node assessment : pN0 or PN1\n* Women aged 18 and over\n* Patients without chemotherapy after operation\n\nExclusion Criteria:\n\n* Patients with negative hormone receptor \uff08both estrogen and progesterone receptor are negative\uff09\n* Human epidermal growth factor receptor 2 \uff08HER2\uff09 positive\n* Pathological nodule evaluation: pN2 or pN3\n* Male patients\n* Patients receiving chemotherapy after surgery",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}